Erythropoietin (Epo) and Venofer Trial After Autologous Hematopoietic Stem Cell Transplantation (HSCT)
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Clinical Trials Related to Hematological Malignancies
Related studies linked through entity extraction aliases.
Open-Label Study Designed to Evaluate the Safety and Preliminary Efficacy of ApoCell for the Prevention of Acute GvHD
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)
- Status
- TERMINATED
- Phase
- PHASE2
A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-versus-host Disease
- Status
- COMPLETED
- Phase
- PHASE2
Intermittent Use of Aerosolized Ribavirin for Treatment of RSV
- Status
- COMPLETED
- Phase
- PHASE4
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Infusion of Donor Lymphocytes Transduced With the Suicide Gene HSV TK in Patients With Haematological Malignancies
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Nonmyeloablative Stem Cell Transplant in Elderly
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Rituximab for Prevention of Chronic GVHD
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
An Evaluation of the Effect of 'Open Window' on Psychological Well-being and Experience of Stem Cell Transplantation
- Status
- COMPLETED
- Phase
- NA
Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC])
- Status
- COMPLETED
- Phase
- NA
RCT to Investigate Whether an Exercise Programme Improves the Physical Performance and QOL After BMT
- Status
- UNKNOWN
- Phase
- NA
MiniMUD Study - Unrelated Reduced Intensity Conditioning With Treosulfan® for Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies
- Status
- UNKNOWN
- Phase
- PHASE2
STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematologic Malignancies and Patients With Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Study of ABT-751 in Patients With Refractory Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE1